The global extracorporeal membrane oxygenation market size was valued at USD 236.7 million in 2015 and is expected to grow at CAGR of 4.3% over the forecast period. The rising incidences of respiratory failure and cardiopulmonary disease coupled with the surging prevalence of COPD (Chronic Obstructive Pulmonary Disease) are anticipated to boost the market growth.
According to the data presented by the American Lung Association, COPD was identified as the third leading cause of deaths in the U.S.in 2013. Furthermore, there were about 11 million people in the U.S alone, diagnosed with COPD whereas 24 million people were estimated to remain undiagnosed.
North America extracorporeal membrane oxygenation market share, by application, 2013-2024 (USD Million)
Moreover, the upward trend in the adoption of unhealthy lifestyle changes and the subsequent development of lifestyle disorders are expected to further augment the COPD incidence rate. Identified risk factors, such as the rising tobacco consumption trend in both, males and females, are the high impact rendering drivers for this market.
With respiratory conditions on the rise and the growing popularity of the ECMO machines in hospitals and other healthcare settings, employed to deliver auxiliary oxygen support in cases of cardiac failure is anticipated to strengthen the demand of this vertical. ECMO machines are used frequently for neonate, pediatric, and adult patients suffering from respiratory conditions; owing to the sensitive nature of this target population that creates the demand for these machines, the adoption rate of these appliances is set to escalate.
The rise inthe uptake of these machines due to the related advantages has triggered the advancement of theunderlying technology utilized in the ECMO machines. With technological refinements underway, the market is expected to experience a boost in its growth during the forecast period.
The key modalities are segmented into the following segments on the basis of the different ways of setting up an ECMO circuit: veno-arterial, veno-venous, and arterio-venous. They areemployed to facilitate the gas exchange process and provide hemodynamic supportin patients with respiratory or cardiac failure.
The veno-arterial ECMO circuit provides both hemodynamic and gas exchange support by bypassing the patient’s lung and heart and diverting the blood flow viathe ECMO circuit; whereas the veno-venous circuit provides solely gas exchange support such that it returns the blood to the heart prior to pulmonary circulation. According to the U.S. National Institute of Health, veno-arterial and veno-venous circuits are used in combination in certaincases, such as during cardiogenic shock.
The market on the basis of applications is categorized asrespiratory, cardiac, and extracorporeal cardiopulmonary resuscitation. All these segments are further sub-segmented into neonate, pediatric and adult application areas. The respiratory-based ECMO segment dominated the market in 2015 with over 40.0% share globally.
The increasing number of patients suffering from respiratory conditions and the rising prevalence of COPD, such as emphysema and chronic bronchitis, along with the widespread upsurge in the health awareness are anticipated to propel the demand significantly.
According to the U.S. National Center for Health Statistics, in the year 2014, about 8.7 million and 3.4 million adults in the U.S. were suffering from chronic bronchitis and emphysema, respectively; this heightened number of individuals with respiratory impairments is further expected to accelerate the emergence of this vertical over the forecast period.
Geographically, the extra corporeal membrane oxygenation market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA. The availability of well-developed primary, secondary, and tertiary care hospitals supported the growth of this vertical in the North America region. Moreover, a well-developed reimbursement network, favorable government funding, and the increasing awareness regarding the ECMO machines facilitated its adoption in hospitals at a faster pace.
In addition, refinements in the present technology in use, such as the CAPIOX FX oxygenator by Terumo Cardiovascular Systems Corporationutilizes hollow fiber technology that offers complete process control and helps in increasing the blood flow rate.
The Asia Pacific region is anticipated to witness the fastest growth owing to the rise in number of patients with respiratory failure and cardiopulmonary conditions, such as emphysema, asthma, and chronic bronchitis. According to the World Health Organization, over 3 million people in Japan suffered from asthma in 2015 among which 70% were determined to be severe cases while 30% were afflicted with a moderate asthma condition.
Some key players operating in the extracorporeal membrane oxygenation market include MAQUETHolding B. V. & Co. KG, Microport Scientific Corporation, Medos Medizintechnik AG, Sorin Group, Medtronic, Plc., Terumo Cardiovascular Systems Corporation, and Nipro Medical Corporation.The new product development and technological introductions to the existing product portfolioare the key strategic initiatives practiced by the companiesin this vertical to sustain themselves in the competition.
For instance, the Minimax Plus Oxygenation System by Medtronic Plc is designed for patients of wide-ranging ages from neonates to children with advanced features, such as low arterial port and venous air director, which are integrated into the system to enhance the system’s performance and increase safety levels.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."